Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib Access Protocol in Japan
NCT02382796Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- May 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Number of Participants Who Were Previously Treated With Dacomitinib on the Parent Study in Japan and Who Got Access to Dacomitinib in This Extension Study at 4 years. Started Jul 2015; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02382796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382796.